Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Gene signature of residual risk following endocrine treatment in early breast cancer

Gene signature of residual risk following endocrine treatment in early breast cancer

US Patent 11566292 · Granted Jan 31, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Cancer risk based on tumour clonality2025
Mitochondrial DNA prostate cancer marker and related systems and methods2022
Methods and devices for predicting anthracycline treatment efficacy2022
Methods and devices for predicting anthracycline treatment efficacy2022
Targeting the histone pathway to detect and overcome anthracyclin resistance2021
Biopsy-driven genomic signature for prostate cancer prognosis2020
Materials and methods for prognosing lung cancer survival2011